Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

FDG-PET predicts outcomes of treated bone metastasis following palliative radiotherapy in patients with hepatocellular carcinoma.

Choi SH, Chang JS, Jeong YH, Lee Y, Yun M, Seong J.

Liver Int. 2014 Aug;34(7):1118-25. doi: 10.1111/liv.12487. Epub 2014 Mar 6.

PMID:
24528941
2.

FDG PET uptake as a predictor of pain response in palliative radiation therapy in patients with bone metastasis.

Adli M, Kuzhan A, Alkis H, Andic F, Yilmaz M.

Radiology. 2013 Dec;269(3):850-6. doi: 10.1148/radiol.13121981. Epub 2013 Oct 28.

PMID:
23985277
3.

Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy.

Kim JW, Seong J, Yun M, Lee IJ, Yoon HI, Cho HJ, Han KH.

Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1172-8. doi: 10.1016/j.ijrobp.2010.11.076. Epub 2011 May 11.

PMID:
21570203
4.

FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients With Bone Metastasis From Non-small-cell Lung Cancer.

Zhao F, Ding G, Huang W, Li M, Fu Z, Yang G, Kong L, Zhang Y, Yu J.

Clin Lung Cancer. 2015 Nov;16(6):e111-9. doi: 10.1016/j.cllc.2015.01.005. Epub 2015 Feb 2.

PMID:
25736696
5.

18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma.

Kim BK, Kang WJ, Kim JK, Seong J, Park JY, Kim DY, Ahn SH, Lee DY, Lee KH, Lee JD, Han KH.

Cancer. 2011 Oct 15;117(20):4779-87. doi: 10.1002/cncr.26099. Epub 2011 Apr 5.

6.

18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.

Huang WY, Kao CH, Huang WS, Chen CM, Chang LP, Lee MS, Chao HL, Chiu CH, Lo CH, Jen YM.

J Nucl Med. 2013 Oct;54(10):1710-6. doi: 10.2967/jnumed.112.119370. Epub 2013 Aug 22.

7.

Fluorodeoxyglucose Uptake on Positron Emission Tomography Is a Useful Predictor of Long-Term Pain Control After Palliative Radiation Therapy in Patients With Painful Bone Metastases: Results of a Single-Institute Prospective Study.

Tahara T, Fujii S, Ogawa T, Michimoto K, Fukunaga T, Tanino T, Uchida N, Matsuki T, Sakamoto H.

Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):322-8. doi: 10.1016/j.ijrobp.2015.10.036. Epub 2015 Oct 30.

PMID:
26853340
8.

Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).

Edet-Sanson A, Dubray B, Doyeux K, Back A, Hapdey S, Modzelewski R, Bohn P, Gardin I, Vera P.

Radiother Oncol. 2012 Feb;102(2):251-7. doi: 10.1016/j.radonc.2011.07.023. Epub 2011 Aug 30.

PMID:
21885145
9.

[Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma].

Kong YH, Han CJ, Lee SD, Sohn WS, Kim MJ, Ki SS, Kim J, Jeong SH, Kim YC, Lee JO, Cheon GJ, Choi CW, Lim SM.

Korean J Hepatol. 2004 Dec;10(4):279-87. Korean.

10.

Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).

Specht JM, Tam SL, Kurland BF, Gralow JR, Livingston RB, Linden HM, Ellis GK, Schubert EK, Dunnwald LK, Mankoff DA.

Breast Cancer Res Treat. 2007 Sep;105(1):87-94. Epub 2007 Feb 1.

PMID:
17268819
11.

The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.

Zerizer I, Al-Nahhas A, Towey D, Tait P, Ariff B, Wasan H, Hatice G, Habib N, Barwick T.

Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1391-9. doi: 10.1007/s00259-012-2149-1. Epub 2012 May 30.

PMID:
22644713
12.

Defining the role of palliative radiotherapy in bone metastasis from primary liver cancer: an analysis of survival and treatment efficacy.

Habermehl D, Haase K, Rieken S, Debus J, Combs SE.

Tumori. 2011 Sep-Oct;97(5):609-13. doi: 10.1700/989.10720.

13.

Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.

Kim YK, Lee KW, Cho SY, Han SS, Kim SH, Kim SK, Park SJ.

Liver Transpl. 2010 Jun;16(6):767-72. doi: 10.1002/lt.22069.

14.

Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan.

Lee JE, Jang JY, Jeong SW, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Jin SY, Choi DL.

World J Gastroenterol. 2012 Jun 21;18(23):2979-87. doi: 10.3748/wjg.v18.i23.2979.

15.

PET/CT characteristics of isolated bone metastases in hepatocellular carcinoma.

Ho CL, Chen S, Cheng TK, Leung YL.

Radiology. 2011 Feb;258(2):515-23. doi: 10.1148/radiol.10100672. Epub 2010 Nov 9.

PMID:
21062922
16.

Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.

Lee JH, Park JY, Kim DY, Ahn SH, Han KH, Seo HJ, Lee JD, Choi HJ.

Liver Int. 2011 Sep;31(8):1144-9. doi: 10.1111/j.1478-3231.2011.02541.x. Epub 2011 May 3.

PMID:
21745288
17.

18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma.

Song MJ, Bae SH, Lee SW, Song DS, Kim HY, Yoo IeR, Choi JI, Lee YJ, Chun HJ, Lee HG, Choi JY, Yoon SK.

Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):865-73. doi: 10.1007/s00259-013-2366-2. Epub 2013 Feb 22.

PMID:
23436073
18.

Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE.

Song HJ, Cheng JY, Hu SL, Zhang GY, Fu Y, Zhang YJ.

Clin Radiol. 2015 Feb;70(2):128-37. doi: 10.1016/j.crad.2014.09.020. Epub 2014 Nov 4.

PMID:
25459673
19.

FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.

Kitagawa Y, Sano K, Nishizawa S, Nakamura M, Ogasawara T, Sadato N, Yonekura Y.

Eur J Nucl Med Mol Imaging. 2003 Jan;30(1):63-71. Epub 2002 Oct 26.

PMID:
12483411
20.

Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET.

Sabet A, Ahmadzadehfar H, Bruhman J, Sabet A, Meyer C, Wasmuth JC, Pieper CC, Biersack HJ, Ezziddin S.

Nuklearmedizin. 2014;53(2):39-45. doi: 10.3413/Nukmed-0622-13-09.

PMID:
24777354

Supplemental Content

Support Center